News

Monday, 22. February 2021 | Filed under Company News

Company News: SEQ-IT Reports Breakthrough in the Rapid Variant Diagnosis of SARS-CoV-2

SEQ-IT, a leading molecular services provider, today announced they completed a novel mass spectrometry based rapid test for the detection of 20 of the most relevant SARS-CoV-2 mutations including the UK (B.1.1.7), South African and Brazilian variants. The test panel was developed using Agena Bioscience’s MassARRAY® System, a well-established tool used by clinical laboratories worldwide to deliver affordable, highly accurate genomic testing.

Read more…

Tuesday, 9. February 2021 | Filed under Company News

Company News: Cardior’s pioneering miRNA approach in heart failure endorsed by expert opinions in the European Heart Journal

— First-ever development of an RNA therapeutic for heart failure

— Successful translation of unique scientific discovery into first-in-class clinical program

Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that the Phase Ib results as well as preclinical and large-animal data of the Company’s lead compound CDR132L were published alongside with two editorials from independent experts in the European Heart Journal Volume 42, Issue 3, January 14, 2021, an issue focusing on ischemic heart diseases.

Cardior’s CDR132L: First-ever RNA-therapeutic addressing cardiovascular diseases advanced into the clinic Read more…

Monday, 8. February 2021 | Filed under Company News

Company News: Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center

– Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies

– Seed investment by Swanbridge Capital and Van Herk Ventures with support from Health~Holland

Pan Cancer T B.V., a biotech spin-off from the Erasmus Medical Center founded by Prof. Dr. Reno Debets (CSO) and Dr. Dora Hammerl (VP R&D), announces the closing of a seed investment and start of operations. Together with Katrien Reynders-Frederix (CEO), the team is committed to the discovery and development of novel TCR therapies against solid tumors such as triple negative breast cancer, bladder cancer, lung cancer, and glioma. Seed investors are Swanbridge Capital and Van Herk Ventures, and the Company is further awarded a Health~Holland grant for a public-private-partnership with Erasmus Medical Center.

Read more…